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Abstract 
An infection and treatment protocol is used to vaccinate cattle against Theileria parva 
infection. Due to incomplete cross-protection between different parasite isolates, a mixture of 
three isolates, termed the Muguga cocktail, is used for vaccination. While vaccination of 
cattle in some regions provides high levels of protection, some animals are not protected 
against challenge with buffalo-derived T. parva. Knowledge of the genetic composition of the 
Muguga cocktail vaccine is required to understand how vaccination is able to protect against 
field challenge and to identify the potential limitations of the vaccine. The aim of the current 
study was to determine the extent of genetic and antigenic diversity within the parasite 
isolates that constitute the Muguga cocktail. High throughput multi-locus sequencing of 
antigen-encoding loci was performed in parallel with typing using a panel of micro- and mini-
satellite loci. The former focused on genes encoding CD8+ T cell antigens, believed to be 
relevant to protective immunity. The results demonstrate that each of the three component 
stocks of the cocktail contains limited parasite genotypic diversity, with single alleles 
detected at many gene/satellite loci and, moreover, that two of the components show a very 
high level of similarity. Thus, the vaccine incorporates very little of the genetic and antigenic 
diversity observed in field populations of T. parva. The presence of alleles at low frequency 
(<10%) within vaccine component populations also points to the possibility of variability in 
the content of vaccine doses and the potential for loss of allelic diversity during tick passage. 
The results demonstrate that there is scope to modify the content of the vaccine in order to 
enhance its diversity and thus its potential for providing broad protection. The ability to 
accurately quantify genetic diversity in vaccine component stocks will facilitate improved 
quality control procedures designed to ensure the long-term efficacy of the vaccine. 
Keywords: Theileria parva; Vaccination; Cattle; Antigenic diversity; Gene sequencing; 
Satellite DNA 
  
 
1. Introduction 
Live vaccines are available for a number of economically important diseases of farm 
animals caused by protozoal parasites including Babesia bovis, Theileria parva and Theileria 
annulata in cattle, Toxoplasma gondii in sheep and Eimeria spp. in poultry (reviewed by 
McAllister, 2014). Extensive efforts to develop alternative, more easily manufactured, 
vaccines based on use of defined antigens, have met with limited success. Hence, 
vaccination against these diseases will continue to rely on the available live vaccines for the 
foreseeable future. Similar slow progress in developing subunit vaccines for malaria has also 
prompted recent efforts to develop a live vaccine using Plasmodium sporozoites harvested 
from infected mosquitos (Hoffman, 2012; Hodgson et al., 2015). Antigenic heterogeneity is 
an important feature of some of these protozoa, notably T. parva (Morrison et al., 2015) and 
Eimeria tenella (Blake et al., 2015), requiring the inclusion of more than one parasite 
genotype in the vaccines.  
Theileria parva, transmitted by Rhipicephalus appendiculatus ticks, causes an acute 
lymphoproliferative disease of cattle, which is a major constraint to livestock production 
throughout a large part of east and southern Africa. Due to the fatal nature of the disease in 
cattle and shortcomings of therapeutic drugs and measures to control tick infestation, 
vaccination offers the most sustainable means of controlling the disease. A method of 
vaccination, involving infection of cattle with T. parva sporozoites and simultaneous 
treatment with long-acting tetracycline, referred to as the infection and treatment method, 
was developed over 40 years ago (Radley et al., 1975). The initial work demonstrated that 
immunisation with one parasite isolate resulted in solid, long-lasting immunity against 
challenge with the same isolate; however, a proportion of animals remained susceptible to 
challenge with other isolates (Radley et al., 1975). Following a series of immunisation and 
challenge experiments, a combination of three parasite isolates was identified, which 
generated immunity against experimental challenge with a range of T. parva isolates of 
cattle origin (Radley et al., 1975) and against field challenge (Radley, 1978). This vaccine, 
commonly referred to as the Muguga cocktail, contains the Muguga, Kiambu 5 and 
  
 
Serengeti isolates of T. parva. The former two isolates were derived by feeding ticks on 
infected cattle, whereas the Serengeti component was originally isolated by feeding ticks on 
an African buffalo after which it was adapted to cattle through tick passage (Young and 
Purnell, 1973). Until recently, use of the Muguga cocktail vaccine in the field has been 
limited, largely due to the complex process involved in production and quality control of 
sporozoites and the requirement for a cold chain to store and distribute the vaccine. 
However, a recent initiative to establish a centre for vaccine production 
(http://www.galvmed.org/en/livestock-and-diseases/livestock-diseases/east-co) and systems 
to facilitate its distribution have led to increased field uptake. 
Despite evidence of efficacy of the Muguga cocktail vaccine in some field settings (Di 
Giulio et al., 2008; Martins et al., 2010), failure to protect a proportion of immunized animals 
has been observed following exposure to tick challenge in a paddock experimentally seeded 
with buffalo-derived T. parva (Radley et al., 1979). Moreover, in more recent studies, 
vaccinated animals exposed to natural field challenge in sites grazed by buffalo were found 
to be susceptible to challenge (Bishop et al., 2015; Sitt et al., 2015). As indicated previously 
(Bishop et al., 2001), more detailed knowledge of the genetic composition of the Muguga 
cocktail vaccine is required, not only to understand how the vaccine content relates to its 
ability to protect against field challenge with T. parva but also to facilitate quality control 
during vaccine production. Although the protective capacity of the vaccine is believed to 
reflect genotypic diversity of the constituent parasites at antigen-encoding loci, information 
on the genetic composition of the parasite populations within each of the vaccine 
components is limited. Allelic polymorphism of three genes encoding antigens recognised by 
immune sera has been documented in the components of the Muguga cocktail using 
restriction fragment length polymorphism analysis and/or monoclonal antibody reactivity 
(Geysen et al., 1999; Bishop et al., 2001). More recently, a whole-genome sequencing 
approach has been applied to characterising Muguga cocktail component stocks (Norling et 
al., 2015). While this confirmed genetic diversity among the components, intra-component 
  
 
diversity was not detected beyond the expected error level of the sequencing platform 
employed. The most discriminant method for examining intra-component genetic diversity to 
date has been the use of micro- and mini-satellite markers; these have been employed to 
demonstrate diversity both between and within the vaccine cocktail components (Oura et al., 
2004, 2007; Patel et al., 2011). 
The short ‘variable number of tandem repeat’ regions detected by micro- and mini-
satellite genotyping are broadly distributed in eukaryotic genomes (Tautz and Renz, 1984). 
As they possess a relatively high rate of mutation, they represent useful markers for high-
resolution molecular fingerprinting of eukaryotic pathogens. These loci, for the most part, do 
not encode proteins involved in stimulating host immunity and can only be used as a proxy 
for assessing antigen diversity if they are closely physically linked to antigen-encoding loci. 
Moreover, micro- and mini-satellite genotyping is not well suited to detecting low abundance 
genotypes within mixed parasite populations, since minor alleles can be difficult to 
differentiate from PCR artefacts. 
Previous studies provided evidence that CD8+ T cell responses specific for parasitised 
lymphoblasts are key mediators of immunity generated by infection and treatment 
vaccination (McKeever et al., 1994; Taracha et al., 1995a). Recently, a number of T. parva 
antigens recognised by CD8+ T cells from immune animals were identified and several of 
these antigens have been shown to be polymorphic in field populations (Pelle et al., 2011). 
In this study, high-throughput multi-locus sequencing of antigen-encoding loci was 
performed, focusing on genes encoding parasite antigens believed to be relevant to 
protective immunity. A panel of micro- and mini-satellite loci was also utilised in order to gain 
a broad understanding of genetic diversity within the Muguga cocktail. 
 
2. Materials and methods 
2.1. Samples and DNA extraction 
  
 
Four batches of Muguga cocktail vaccine stabilate (ILRI 0801 - ILRI 0804) and the 
corresponding reference stabilates (Muguga - 4230; Serengeti - 4229; Kiambu 5 - 4228), 
prepared previously as described by Patel et al. (2016), were used in this study. Both the 
reference stabilates and the vaccine stabilates had been prepared from ticks infected with 
the same parent stabilates (Muguga – 73, Serengeti - 69 and Kiambu 5 – 68). Three batches 
of infected ticks, each obtained from cattle infected with one of the component stabilates (68, 
69 and 73) were used at different times to prepare the reference and vaccine stabilates. The 
latter were prepared from a mixture of ticks from the three batches. Following moulting to 
adults, ticks from each of the batches were fed on rabbits for 4 days and a sample of the ticks 
was used to determine the infection rates in each batch of ticks, based on examination of 
dissected salivary glands. The final mixture of the ticks was prepared to ensure there were 
equivalent numbers of acini infected with parasites from each of the component stabilates. 
The tick mixture was homogenised, suspended in 7.5% glycerol and cryopreserved in 
aliquots in liquid nitrogen (Cunningham et al., 1973b). The four vaccine batches were 
prepared from a subset of the same batches of ticks processed 1 week apart. Following 
preparation of the vaccine stabilates, the three reference stabilates were prepared separately 
from ticks infected with each of the three parasites. These stabilates (4228, 4229 and 4230) 
are currently being used to produce future batches of vaccine. 
An additional sporozoite stabilate (3014) of the Marikebuni T. parva stock was also 
examined. This stock, which has been used on a more limited scale for vaccination by 
infection and treatment (Mutugi et al., 1989), was originally isolated from a field tick 
collection in the coastal district of Kenya and had undergone three laboratory passages 
through ticks (Irvin et al., 1983; Mutugi et al., 1989). This stock was used as a comparator in 
order to investigate how the diversity in a single isolate used for vaccination compares with 
that of the trivalent Muguga cocktail. 
For DNA extraction, excess tick debris was first removed from thawed sporozoite 
stabilates by centrifuging at 100 g for 5 min and the supernatant containing the sporozoites 
transferred to a clean Eppendorf tube. The sporozoites were pelleted at 16,000 g before 
DNA was extracted using the Qiagen DNeasy Blood and Tissue Kit. 
 
  
 
2.2. Micro- and mini-satellite DNA typing 
PCR amplification was performed using micro- and mini-satellite markers described 
by Oura et al. (2003, 2005). Fifteen satellite markers distributed across the four 
chromosomes of the parasite genome were used, namely ms2, MS3, ms7, MS7, MS8, 
MS14, MS15, MS19, MS21, MS25, MS27, MS30, MS33, MS39 and MS40 (genome 
references provided in Katzer et al., 2010). PCR conditions were similar to those described 
previously, except that one primer of each primer pair was labelled at the 5' end with the 
fluorophore FAM (Eurofins Genomics, UK). Allele sizes were determined using capillary flow 
electrophoresis and detection of the fluorophore signal from the labelled primer in each 
amplicon. This was done using GenescanTM technology (Applied BioSystems, UK) with the 
GSLIZ500 size standards. Only peaks in the range of 100 to 500 bp were considered for 
further analysis. The relative abundance of individual peaks was determined and expressed 
as a percentage of the total area under the curve for all peaks of the appropriate colour in 
the trace combined. Peaks with an area of less than 3% of the total area under the curve for 
all peaks were excluded. Traces were inspected and alleles were manually ‘called’. 
F-statistic values were calculated from the mini- and microsatellite typing data from 
the different parasite stocks and were utilised to carry out principal co-ordinate analysis 
(PCoA). The Microsoft plug-in Genalex6 (Peakall and Smouse, 2012) was used to perform 
PCoA. 
 
2.3. Theileria parva CD8+ T cell antigens 
Ten T. parva genes (Tp1-Tp10) known to encode antigens recognised by immune 
CD8+ T cells were investigated. Identification of Tp1 (TP03_0849), Tp2 (TP01_0056), Tp4 
(TP03_0210), Tp5 (TP02_0767), Tp7 (TP02_0244) and Tp8 (TP02_0244) antigens and their 
T cell epitopes has been reported previously (Graham et al., 2006, 2008). The same authors 
also identified a further two antigens, Tp3 and Tp6, corresponding to T. parva genome IDs 
TP01_0868 and TP01_0188, respectively. Tp9 and Tp10 (genome IDs TP02_0895 and 
  
 
TP04_0772, respectively) were identified subsequently by two of the current authors (ND 
MacHugh and SP Graham) using parasite-specific CD8+ T cells to screen a parasite cDNA 
library as described previously (Graham et al., 2006); Tp9 and Tp10 were shown to be 
presented by the 1*02301 and 3*00201 class I major histocompatibility complex (MHC) 
alleles, respectively, and a single CD8+ T cell epitope (Tp967-75 – AKFPGMKKS; Tp10419-427 - 
NNPELIPVL) was identified in each by screening synthetic peptides as described elsewhere 
(Graham et al., 2008). 
 
2.3.1. Sanger sequencing 
The full-length open reading frame (ORF) of the Tp2 and Tp9 genes, and a segment 
of the Tp1 gene, located between nucleotides 523 and 954, were sequenced from a series 
of cloned parasitised cell lines derived from each of the three constituent Muguga cocktail 
parasite stocks (Patel et al., 2011). The primers and PCR conditions used for amplification of 
the Tp1 and Tp2 sequences have been described previously (Pelle et al., 2011). Primers for 
Tp9 (forward: 5'-ATGAATGTTCTAACTACTGG-3'; reverse: 
5'-TTATTGTTTTGTCCATGGTTTATTACG-3') were designed based on the first 20 and the 
last 27 nucleotides of the Tp9 ORF from the Muguga reference isolate F100 TpM (GenBank 
accession number XM_760370). A second set of primers (forward: 5’- 
ACCCCATCCATTTGACAG-3’ and reverse 5’-CCTGGCATTAAGGTACTC-3’), designed to 
amplify a product of 369 bp of the genomic sequence of Tp9, with the forward primer located 
78 bp downstream of the start codon, was used to generate PCR products from the 
Marikebuni stock (stabilate 3014). The PCR conditions used for Tp9 were as described for 
Tp1 and Tp2 (Pelle et al., 2011), except that annealing was performed at 55o C for 1 min and 
the extension at 72o C was for 90 s. The amplicons were processed and sequenced either 
directly or after cloning into a pGEM-T Easy plasmid vector (Promega) and sequenced as 
previously described (Pelle et al., 2011). 
 
  
 
2.3.2. Processing of samples for high throughput sequencing 
A multi-locus sequence typing system was established using Roche (USA) 454 
amplicon sequencing technology in order to identify allelic variants present at a low 
frequency in the vaccine stocks. Primers were designed to amplify segments of 10 genes 
(292 - 492 bp) known to encode antigens capable of recognition by CD8+ T cells (Tp1 - 
Tp10). Regions containing known CD8 T cell epitopes were selected. The primers were 
tested for their ability to generate PCR products from a panel of 32 genotypically diverse 
cloned T. parva-infected cell lines. These clones were derived by limiting dilution from 
established T. parva-infected cell lines and included genetically distinct clones of the 
Marikebuni stock produced by Katzer et al. (2006) (n = 10), and clones derived during the 
course of the current study from isolates from cattle grazed in proximity of buffalo (n = 8) 
(Bishop et al., 2015) and isolates obtained from buffalo (n = 14) (Conrad et al., 1987). 
Specificity was tested using DNA from other Theileria spp., T. annulata, Theileria buffeli, 
Theileria taurotragi and Theileria sp. (buffalo), uninfected bovine peripheral blood 
mononuclear cells (PBMC) and uninfected R. appendiculatus ticks. Several primer 
combinations were tested and for nine genes, primer pairs were identified that gave a 
product of the expected size from each parasite clone which was specific for T. parva (see 
Table 1). In order to take account of genetic polymorphism at the locus encoding Tp2, two 
pairs of primers were designed to ensure amplification of all alleles. The same nucleotide 
positions were targeted by each primer pair in separate reactions and equal quantities of the 
two products were pooled prior to sequencing. A longer amplicon (562 bp) was obtained for 
Tp2 than for the other genes. Efforts to identify primers that would generate a suitably sized 
PCR product for Tp9 from all parasite clones were unsuccessful and therefore this gene was 
not pursued further. 
Each primer was then modified to produce a fusion primer comprising three 
components, an adaptor sequence required for processing of the amplicon for sequencing, a 
10 nucleotide sequence known as the Multiplex Identifier (MID) and the gene-specific primer 
  
 
sequence. The sequences of the adaptors and MIDs used were those described in the 
Roche Technical bulletin (http://454.com/downloads/my454). These fusion primers were 
then re-tested to confirm they yielded PCR products of the expected size. 
Amplicons were generated for the nine genes (Tp1 - Tp8 and Tp10) using the fusion 
primers in combination with a polymerase with proofreading capacity. The primer 
concentrations and annealing temperatures used in each of the PCR assays are shown in 
Table 1. For Tp1, Tp3, Tp4, Tp5, Tp6, Tp7 and Tp8, the reactions comprised 5 µl of 10x 
Fast start High Fidelity reaction buffer containing 18 mM MgCl2 (Roche) and 2.5 units of Fast 
start high fidelity enzyme blend (Roche), 1 µl of DNA and nuclease-free water in a final 
volume of 50 µl. The cycling conditions were as follows: 95 °C for 3 min followed by 30 
cycles for 30 s at 95 °C, 30 s at the temperatures specified in Table 1 and 30 s at 72 °C, 
followed by a final extension at 72 °C for 7 min. The melting temperature for the primers 
designed for the amplification of Tp2 and Tp10 was outside the working range of the Fast 
start high fidelity enzyme blend (49 °C). Therefore products for these genes were obtained 
with a mixture of 1:1 Taq polymerase (Bioline, UK) and Pfu DNA polymerase (Promega, 
UK). The PCR comprised 10 - 20 pmol of each primer (see Table 1), 5 µl of custom PCR mix 
(Bioline), 1 µl of DNA and nuclease-free water in a final volume of 50 µl. The cycling 
conditions were as follows: 95 °C for 3 min followed by 35 cycles of 95 °C for 1 min, 49 °C 
for 1 min and 72 °C for 2 min, followed by a final extension at 72 °C for 7 min. PCR products 
were visualised under UV light in 1.5% agarose gels containing SafeView nucleic acid stain 
(NBS, Biologicals Ltd, UK) and bands corresponding to the product of interest were excised. 
The PCR products were then purified using the Promega Wizard Gel and PCR Clean-up 
System (Promega Corporation, USA). The purity of PCR products was assessed using 
Agilent DNA1000 chips on a 2100 Bioanalyser (Agilent Technologies, USA). PCR products 
were quantified using a picogreen assay (Thermo Fischer Scientific, USA). Equimolar 
quantities of PCR products were pooled and submitted to the Centre for Genomics Research 
(CGR), University of Liverpool, UK for Roche 454 sequencing. 
  
 
 
2.4. Analysis of high throughput sequence data  
Raw 454 sequencing data were processed using a custom bioinformatics pipeline. 
Briefly, reads for individual PCRs were extracted from multiplexed sequence datasets on the 
basis of the MID tags and primer sequences present within each read. As sequence quality 
was reduced towards the end of the relatively long Tp2 reads ,and forward and reverse 
reads could not be paired with confidence, only the first 290 bases of the forward reads were 
analysed for this gene. The raw reads for a single gene in a single sample were then 
subjected to noise reduction (shhh.flows and shhh.seqs) and chimaera detection algorithms 
implemented on the Mothur platform (Schloss et al., 2009). Three different algorithms were 
used in order to maximise the chance of chimaera detection, namely Perseus, Chimera 
slayer and Uchime (Edgar et al., 2011; Haas et al., 2011; Quince et al., 2011). ‘Variants’ at a 
frequency below 0.4% or below five reads were removed from the dataset. These cut-offs 
were chosen based on control experiments where sequences were obtained from every 
gene following amplification from a clonal parasite stock. Resulting sequences were aligned 
using MUSCLE (Edgar, 2004) and visualised using the MEGA 5 phylogenetics suite 
(Tamura et al., 2011). Due to the presence of homopolymeric-length errors, which are 
intrinsic to 454 technology, single nucleotides were added to or deleted from sequence 
reads as necessary when the length of a homopolymer tract differed from that of the most 
abundant allele(s); not correcting such errors would have led to frame shifts and thus a 
change to the translated sequence and/or premature stop codons. Where single base pair 
insertions and deletions altered the reading frame of the gene, these were assumed to be 
artefacts and the reads discarded. 
The aim was to obtain a minimum of 1,200 reads per gene per sample, equating to a 
99.3% chance of detecting five or more reads representing an allele present at a frequency 
of 1%. In some cases, this required data from different sequencing runs to be combined in 
order to obtain sufficient depth. With the exception of the Tp2 gene, the target of obtaining 
  
 
1,200 usable reads per gene was exceeded for all genes in each of the Muguga cocktail 
components; the Tp2 gene yielded approximately 500 reads for each component. 
 
3. Results 
3.1. Micro- and mini-satellite genotyping of the Muguga cocktail stocks 
Genotypic diversity within the T. parva stocks used in the Muguga cocktail was first 
assessed using a panel of 15 micro- and mini-satellite markers distributed across the four 
parasite chromosomes. The use of capillary electrophoresis to detect micro- and mini-
satellite alleles also allowed estimation of the relative proportions of genotypes present in 
each parasite sample. The alleles detected and their relative representation within the three 
parasite stocks are shown in Fig. 1 and the overall diversity of alleles in the Muguga cocktail 
is summarised in Table 2. Overall, each of the stocks showed limited intra-stock diversity. 
Only a single allele was detected for 14 of the 15 loci examined in the Kiambu 5 stock; two 
alleles were found for the remaining locus. Similarly, a single allele was detected with 11 of 
the satellite markers in the Muguga stock and with eight of the satellite markers in the 
Serengeti stock. The remaining four satellite markers in the Muguga stock and five of the 
remaining markers in Serengeti detected a single additional allele, while two additional 
alleles of MS8 and MS25 were detected in the Serengeti stock. The genotypes of Muguga 
and Serengeti stocks exhibited a high level of similarity, with at least one allele shared 
between the stocks for each of the markers. By contrast, the predominant allele detected 
with 10 of the 15 satellite markers in the Kiambu 5 stock was either unique to this stock 
(three markers) or present as a minor component (<20%) in either or both of the other 
stocks. PCoA based on the level of genetic differentiation between each stock illustrates a 
high level of similarity between the Muguga (Stabilate 4230) and Serengeti (Stabilate 4229) 
stocks and the distinct profile for the Kiambu 5 stock (Fig. 2).  
Subsequently, micro- and mini-satellite typing was conducted on four batches of the 
Muguga cocktail vaccine (ILRI 0801-0804) to determine whether the composition of the 
  
 
parasite cocktail reflected that of the individual components described above (Muguga, 
Serengeti and Kiambu 5). The results are presented in Fig. 3. All alleles found in the 
individual components were present in the vaccine batches, with the exception of a minor 
allele of MS8, which was below the threshold value for acceptance. Similarly, all alleles 
identified in each of the vaccine batches could be identified in one or more component 
stocks. In addition, there was a high level of consistency between batches, both in terms of 
the alleles detected and their relative abundance. PCoA revealed a close similarity between 
the four Muguga cocktail batches, illustrated in Fig. 2 as a tight cluster with little 
differentiation between batches (FST = 0.003+/-0.001). Given that the Muguga and Serengeti 
components were highly similar to one another and that they constitute two-thirds of the 
vaccine cocktail, it was anticipated that the vaccine batches would be more similar to these 
components than the Kiambu 5 component and this was confirmed by the PCoA analysis. 
 
3.2. Antigen gene sequence diversity in the Muguga cocktail component stocks 
Genotypic diversity within and among the T. parva stocks that constitute the Muguga 
cocktail was further investigated by multi-locus sequencing of genes encoding CD8+ T cell 
antigens by applying high throughput sequencing using Roche 454 technology. The number 
of alleles detected for each gene and their relative proportions in each stock are illustrated in 
Fig. 4. Details of the alleles identified among component stocks of the Muguga cocktail are 
summarised in Table 3. With the exception of a single di-nucleotide deletion within an intron 
region of one Tp10 allele, all allelic differences were due to point mutations. 
Despite the considerable sequencing depth achieved, the number of allelic variants 
identified in each of the component stocks was low (one to four alleles). With the exception 
of one gene in Kiambu 5 (Tp3), a single dominant allele accounted for more than 90% of the 
reads obtained for each gene in each of the three stocks. Moreover, the alleles detected 
within each stock and in the different stocks showed a high level of sequence identity 
(> 95%), with the majority of the nucleotide differences not resulting in amino acid 
  
 
polymorphism (Table 3). Amino acid residue polymorphism was found only among alleles of 
Tp2, Tp3, Tp7 and Tp10. 
In the Muguga stock, only a single allele was detected for each gene except Tp6, 
which had a second allele present at low abundance (0.77%), containing four synonymous 
substitutions in the 291 nucleotide sequence with respect to the major allele. Across the loci, 
the same predominant alleles found in the Muguga stock also dominated the Serengeti 
stock, accounting for all of the sequence reads obtained for five of the genes and more than 
90% of reads for the remaining four genes (Tp2, Tp5, Tp6 and Tp10). An additional allele 
was detected for the latter four genes, which differed from the reference Muguga allele by 
between two and 10 nucleotide positions. With the exception of the two mutations in Tp2 
(see Table 3), these differences did not result in an alteration to the predicted amino acid 
sequence. A single allele was detected for six of the genes in the Kiambu 5 stock, two of 
which (Tp1 and Tp8) were identical to that found in the Muguga stock and four (Tp2, Tp5, 
Tp6 and Tp10) were identical to the minor alleles found in the Serengeti stock. The 
remaining three genes, Tp3, Tp4 and Tp7, shared one allele with Muguga or Serengeti 
stock, but also had between one and three additional alleles. The two additional alleles for 
Tp3 had residue changes over nine and 10 nucleotide positions compared with the Muguga 
allele, leading to three and four amino acid changes, respectively. The three variant Tp4 
alleles had between 21 and 31 nucleotide substitutions compared with the Muguga allele, 
but all were within an intron and hence did not alter the coding sequence. The Tp7 variant 
allele contained seven nucleotide substitutions over the length of the amplicon (253 bp), 
leading to only one amino acid change. 
 
3.3. Antigenic diversity in the Muguga cocktail component stocks 
Previous studies have identified CD8 epitopes in six of the nine antigen genes 
examined (Graham et al., 2008) and a single epitope in Tp10 is reported in the present 
study. Alleles containing amino acid coding changes were only detected in two of these 
  
 
genes. The single amino acid substitution found in Tp7 lies outside the epitope-encoding 
region. However, the two amino acid changes in Tp2 both lie within one of the defined 
epitopes (Tp227-37) and result in substitutions at positions 2 (H→D) and 6 (K→N) of the 
epitope (Table 4). 
 
3.4. Analyses of Tp9 sequence diversity by Sanger sequencing 
3.4.1. Demonstration of sequence polymorphism in the Tp9 gene 
The initial failure to design primers that could reproducibly generate PCR products 
suitable for 454 sequencing from the Tp9 gene suggested that this gene is polymorphic. 
Sanger sequencing was therefore conducted on full-length PCR products from cloned 
sporozoite stabilates of five cattle-derived T. parva isolates – Muguga, Boleni, Uganda, 
Mariakani and Marikebuni (Morzaria et al., 1995). The Tp9 sequences obtained from the 
cloned Muguga and Uganda parasites were identical to the 1,005 bp reference Muguga 
gene, but each of the other clones contained a different allele (GenBank IDs: JN828541, 
JN828544, JN828549, JN828552). The Boleni sequence was similar to the Muguga 
reference, differing only by the presence of a 30 nucleotide insert in the central region of the 
gene. The Mariakani and Marikebuni Tp9 sequences were highly divergent from the 
reference due to numerous amino acid substitutions as well as several insertions and 
deletions. The latter resulted in differences in the length of the coding region (957 bp for 
Mariakani and 1,107 bp for Marikebuni). Translation of these sequences confirmed four 
alleles of the Tp9 protein (Supplementary Fig. S1). The CD8+ T cell epitope identified in Tp9 
exhibited amino acid substitutions in six of the nine amino acids in both the Marikebuni and 
Mariakani sequences, which differed from each other at two residues. 
 
3.4.2. Analysis of Tp9 in the Muguga cocktail components 
PCR amplicons of Tp9 obtained from a series of cloned T. parva-infected cell lines 
derived from each of the three Muguga cocktail stocks were subjected to Sanger 
  
 
sequencing. These cloned lines comprised 20 lines infected with Muguga parasites, 10 with 
Serengeti and 11 with Kiambu 5. Sequences were also determined for Tp1 and Tp2. The 
findings for both of these genes were consistent with the results of the 454 sequencing, in 
that only one variant sequence of Tp2, present in all of the Kiambu clones and in all except 
two of the 10 Serengeti clones, was found. In the case of Tp9, all of the sequences of the 
Muguga and Serengeti clones were identical to the genome reference sequence, whereas 
all 11 clones of Kiambu 5 had a distinct allele (Supplementary Fig. S1), which was very 
similar to that described above for the Mariakani isolate, differing only at five nucleotide 
positions and encoding an additional amino acid residue within the first 17 nucleotides. 
 
3.5. Antigen gene sequence diversity in the Marikebuni stock  
Multi-locus 454 sequencing of the same set of nine genes was performed on the 
Marikebuni stock of T. parva. The results are illustrated in Fig. 4 and summarised in Table 5. 
Single alleles, which were identical to the Muguga genome reference sequence, were 
detected for four of the genes (Tp3, Tp4, Tp6 and Tp8). Two alleles were identified for three 
genes (Tp1, Tp5, and Tp7) and four alleles for the remaining two genes (Tp2 and Tp10). Six 
of these alleles (one for Tp1, two for Tp2, one for Tp7 and two for Tp10) were distinct from 
those found in the Muguga cocktail. In all cases, a single allele accounted for more than 90% 
of the sequence reads. With the exception of Tp2, the level of sequence divergence between 
alleles was very low. The sequence polymorphism resulted in amino acid substitutions in 
defined CD8+ T cell epitopes in only two of the antigens (Table 5). A single allelic variant was 
found for the Tp1214-224 epitope and two allelic variants were detected for all three Tp2 
epitopes represented in the partial sequence reads obtained for this gene (Tp227-37, Tp240-48, 
Tp249-59). The epitope variants differed by between one and six amino acid residues from the 
reference sequence (Table 4). 
Sanger sequencing of 17 clones of the partial Tp9 DNA amplified by PCR from the 
Marikebuni stock revealed four alleles, including one identical to the Muguga reference 
  
 
sequence (11 clones). A further allele differed by only two nucleotides from the reference 
sequence (two clones), leading to one amino acid change. The other two alleles were similar 
to each other (two clones each) (only differing at one nucleotide position, leading to an 
amino acid change), but differed from the Muguga allele at 44 nucleotide residues, leading to 
28 amino acid substitutions, and had a 9 bp deletion. 
 
3.6. Comparison of diversity with that of field populations of T. parva 
Previous studies of the sequences of the Tp1 and Tp2 genes in field populations of 
T. parva have shown that both genes exhibit extensive allelic diversity, which was 
particularly marked in buffalo-derived parasite isolates (Pelle et al., 2011). Herein, we have 
also detected four alleles of the Tp9 gene in a small sample of cattle-derived parasite 
isolates. A comparison of these findings, with sequence data obtained for Tp1, Tp2 and Tp9 
from the Muguga cocktail and the Marikebuni stock, is presented in Table 6. In contrast to 
the large number (more than 25) of amino acid sequence variants of Tp1 and Tp2 detected 
by Pelle et al. (2011) in 82 field isolates of T. parva, the Muguga cocktail contained no Tp1 
variants and only a single variant allele of Tp2 in addition to the reference Muguga alleles of 
the two genes. Moreover, the Tp2 variant was antigenically similar to the reference 
sequence, differing at only one of the six defined CD8+ T cell epitopes identified in this 
antigen. The more limited sequence data obtained for Tp9 revealed only one amino acid 
variant, in addition to the genome reference sequence, within the Muguga cocktail. Hence, 
with respect to these antigens, the Muguga cocktail incorporates very little of the observed 
diversity in field populations of T. parva. 
The results obtained for the Marikebuni stock revealed one, two and three sequence 
variants of Tp1, Tp2 and Tp9, respectively, in addition to the genome reference sequence. 
These included alleles that showed extensive divergence in the encoded amino acid 
sequence including the CD8+ T cell epitopes. Hence, the Marikebuni stock contains greater 
diversity in these antigens than the Muguga cocktail. 
  
 
 
4. Discussion 
The aim of this study was to use multi-locus sequencing of genes encoding currently 
identified CD8+ T cell antigens in combination with micro- and mini-satellite genotyping, to 
determine the extent of genetic and antigenic diversity in the components of the Muguga 
cocktail live T. parva vaccine. The results indicate that, overall, the Muguga cocktail vaccine 
incorporates very little of the genetic and antigenic diversity observed in field populations of 
T. parva. 
Roche 454 sequencing of PCR amplicons of antigen-encoding genes was utilised in 
order to provide greater resolution than had been achieved in previous studies. Preliminary 
experiments indicated reliable detection of sequence variants present at 0.4% using this 
method. Use of capillary electrophoresis to detect micro- and mini-satellite alleles also 
allowed estimation of the relative proportions of genotypes present in each parasite sample. 
In agreement with previous micro- and mini-satellite genotyping results obtained by Oura et 
al. (2004), a limited amount of diversity was observed within the components of the Muguga 
cocktail. Despite the higher resolution afforded by high-throughput sequencing with respect 
to the detection of rare alleles, this method also revealed limited but appreciable diversity 
within the vaccine components. A major contributory factor to the overall limited diversity 
within the Muguga cocktail as a whole was the large number of loci where the Muguga and 
Serengeti components shared either a single or a clearly predominant allele. This similarity 
is re-inforced by the whole-genome sequencing effort recently applied to the vaccine 
component stocks using a gene capture method (Norling et al., 2015), which did not provide 
evidence of intra-component diversity. However, interestingly, in that study no bi-allelic 
single nucleotide polymorphisms (SNPs) were identified within the Serengeti transformed 
stock (which we found to be relatively homogeneous) while 18 SNPs were identified within 
Kiambu 5. While the number of putative SNPs was noted to be within the error rate of the 
sequencing platform used in that study and the component stock assumed to be clonal, the 
  
 
present targeted amplicon sequencing approach clearly demonstrates that Kiambu 5 is 
heterogeneous with, for example, the Tp3 locus displaying three alleles and an estimated 
heterozygosity of approximately 53% (Fig. 4). The discrepancy is almost certainly due to the 
greater ability of the methods used in the current study to detect alleles present at low 
frequency.  
In view of the diverse origins of the parasite stocks, it is surprising to find such a high 
degree of similarity between the Serengeti and Muguga parasites. The Serengeti stock was 
originally isolated from buffalo (Young and Purnell, 1973), in which the T. parva population is 
known to possess enormous genotypic diversity (Oura et al., 2011; Pelle et al., 2011). 
Although buffalo T. parva parasites readily infect cattle and cause severe disease, they 
usually differentiate poorly to the tick-infective intra-erythrocytic stage and therefore onward 
transmission via the tick either does not occur or does so with very low efficiency (Barnett 
and Brocklesby, 1966; Mbizeni et al., 2013). The limited diversity in the Serengeti stock 
could be explained by a bottleneck in the cattle-tick cycle, in which only a small subset of the 
parasites in the original Serengeti could adapt to continued passage through cattle and ticks. 
However, the likelihood that the selected parasite would be highly similar to the Muguga 
isolate seems remote and therefore these findings raise the possibility that the Serengeti 
stock has become contaminated with parasites from the Muguga stock at some time 
following its isolation from the field. This has also been suggested recently by Norling et al. 
(2015), based on genome sequence data. 
The parasite stocks currently used for the production of the Muguga cocktail have 
undergone several cattle-tick-cattle passages since the formulation of the Muguga cocktail in 
the 1970s and, at least for the Serengeti stock, it appears very likely the composition of the 
stock has changed since its isolation. Micro- and mini-satellite DNA typing and high-
throughput multi-locus sequence typing reveal the presence of alleles at a low frequency in 
the vaccine and each of its component parts. As each component has been maintained in 
isolation, it is logical to view each as a sub-population of T. parva genotypes. Field studies of 
  
 
T. parva have previously documented appreciable polymorphism at a number of the antigen 
(Pelle et al., 2011) and satellite marker loci (Oura et al., 2005, 2011) used in this study. 
Moreover, mixed genotypes were frequently detected in single samples from naturally 
infected animals (Oura et al., 2005). It is interesting to note that within each of the three 
individual vaccine component stocks, the majority of loci display no polymorphism while 
others show two to four alleles. In broad terms, therefore, the genotypes within a component 
can be said to share a remarkably high degree of similarity. This lies in contrast to the low 
level of similarity which two unrelated field isolates would be expected to share. It can 
therefore be surmised that each component stock represents a highly inbred parasite 
population. As each stock has undergone extensive cattle-tick-cattle passage in isolation, it 
is likely that the present day stocks represent an inbred population derived from the original 
field isolates. Each component is genetically isolated and will have a small effective 
population size. The parasite may, therefore, be subjected to significant bottlenecking 
through stochastic processes related to the limited number of cattle/ticks used to maintain 
the population coupled with the potential for selection of particular genotypes in the cattle 
host. Consequently, it may be hypothesised that two evolutionary ‘drivers’ will act to reduce 
the diversity at each locus – selection and genetic drift. 
Mathematical modelling of field data suggests that a large proportion of tick 
transmissions of T. parva are from carrier cattle, i.e. animals with persistent infection 
following resolution of the acute phase of infection (Medley et al., 1993). There is also 
evidence that carrier cattle can acquire infection with additional parasite genotypes following 
tick challenge, thus resulting in carriage of mixed genotypes (Oura et al., 2007), which have 
the potential to recombine during subsequent transmission by ticks. The selective pressures 
in the field, where carrier infections play a prominent role in transmission, are likely to be 
different than those experienced by laboratory stocks, which are maintained in isolation by 
repeated tick passage from acutely infected cattle. Hence, it seems likely that different 
parasite genotypes will have differing levels of fitness in the course of this regime of passage 
  
 
through the parasite life-cycle. Consequently, genotypes with loci conferring a long-term 
passage ‘fitness’ would be positively selected in each component population and genetically 
linked regions surrounding such loci would also be selected by way of a genetic hitch-hiking 
effect. In addition to any selective pressure, given that the parasite population is relatively 
small and isolated, it is likely that genetic drift will result in alleles being lost from each 
component population in a stochastic manner during the course of successive passages. It 
has been demonstrated previously that changes to the parasite population can occur with 
additional cattle-tick passages for the Marikebuni stock, a stock that has also been used for 
immunisation in the field (Katzer et al., 2006). The current study demonstrated that an early 
passage of the Marikebuni stock (stabilate 3014) contained relatively greater diversity than 
any of the Muguga cocktail components. However, by applying micro- and mini-satellite 
genotyping to sequential passages of this stock, Katzer et al. (2006) identified changes in 
allele frequencies at each passage. This resulted in a stock that was quite distinct from the 
original after only three rounds of passage, with a minor component becoming dominant in 
the latter. It is of note that the Muguga stock, which has very limited diversity, has been 
subjected to prolonged passage, having been maintained by regular tick passage following 
its isolation in 1961 until the early 1970s when procedures for cryopreservation were 
developed (Cunningham et al., 1973b). Unfortunately, without archive material with which to 
determine the early composition of the component stocks of the Muguga cocktail, it is 
impossible to estimate the scale of loss of genetic diversity through time. Nevertheless, the 
possibility of genetic selection/drift poses a clear and present threat to the stability of each of 
the vaccine components as they are maintained by cattle-tick passage, with low frequency 
alleles being at greatest risk. Although the present study demonstrates that four batches of 
vaccine prepared at different time points from the same batches of infected ticks show very 
similar composition of parasite genotypes, it is unknown how this consistency is maintained 
when vaccine batches are produced using stabilates that have undergone additional cattle-
tick passage. Another concern is whether the genetic diversity within each component will be 
present within every dose of the Muguga cocktail vaccine. One of the goals of early studies 
  
 
with cryopreserved T. parva sporozoites was to establish a dose of parasites that would 
result in mild clinical reaction with recovery in all animals, which could be used for 
vaccination. However, titrated doses of sporozoites resulted in variable reactions; at doses 
that did not give severe reactions in any animals, some of the animals did not become 
infected, as judged by the absence of detectable parasites and susceptibility to subsequent 
parasite challenge (Cunningham et al., 1973a). Moreover, there was a relatively narrow dose 
range (100 fold) between most animals developing severe reactions and some animals not 
becoming infected, suggesting that a few thousand or fewer infection events in vivo are 
sufficient to result in severe disease. Hence, at the doses used for infection and treatment, it 
is uncertain whether low frequency parasite genotypes will be present in every vaccine dose 
and whether they make a meaningful contribution to the breadth of immunity induced by 
vaccination. 
Despite the concerns regarding parasite composition, vaccination of cattle with the 
Muguga cocktail appears to be effective in the field (Di Guilio et al., 2008). The obvious 
question arising from the results of the current study is why, given its limited diversity, is it 
able to provide broad protection? Our current knowledge of the immunological basis of strain 
specificity of immunity following immunisation with individual parasite isolates indicates that it 
is a consequence of strong immunodominance hierarchies in the antigens recognised by the 
specific CD8+ T cell response, resulting in the response in each animal being focused on a 
few antigens, the most dominant of which tend to be polymorphic in the parasite population 
(reviewed in Morrison et al., 2015). The antigen dominance hierarchy varies between 
animals of different MHC genotypes and can be influenced by the parasite isolate used for 
immunisation (Taracha et al., 1995b). The latter, in part, reflects the capacity of the parasite 
to undergo frequent sexual recombination during transmission of heterogeneous parasite 
populations (Oura et al., 2005; Katzer et al., 2011), such that allelic variants of different 
antigens can occur in different combinations in different parasite genotypes. The specificity 
of responses induced by immunisation with mixtures of parasite isolates has not been 
  
 
investigated. However, since the antigens expressed by each constituent parasite genotype 
will infect different cells and present a different but overlapping repertoire of antigens to 
responding T cells, each parasite might be expected to generate its own CD8+ T cell 
response against different dominant antigens. Consequently, the overall CD8+ T cell 
response is likely to comprise a wider range of antigenic specificities than that induced by 
the individual parasites, increasing the likelihood that one or more of the specificities will 
recognise parasite genotypes encountered upon field challenge. In this model (elaborated 
further in Morrison et al., 2015), the immunising parasites do not necessarily need to include 
all of alleles of each polymorphic antigen to generate broad protection. If this model is 
correct, the precise parasite populations used within a live cocktail vaccine may not be 
critical, providing they are relatively antigenically diverse. To what extent this scenario 
applies to other protozoal pathogens remains unclear. Among those referred to earlier, 
immunity to Eimeria spp. is mediated predominantly by T cell responses (Smith and Hayday, 
2000) and data from cross-immunity studies indicate that a similar immunodominance 
phenomenon may account for the lack of cross-protection between of isolates of Eimeria 
maxima (Smith et al., 2002).   
On the basis of the model proposed above and given the results of the current study, 
we propose that an improved T. parva cocktail could be produced using a mixture of 
genotypically diverse cloned parasites. Given that the Muguga cocktail essentially consists 
of two major components, we hypothesise that three genotypically distinct clones would be 
sufficient to induce a similar or greater breadth of protection than the Muguga cocktail. 
Methods for obtaining sporozoite preparations from cloned parasites are well established 
(Morzaria et al., 1995) and genome sequencing could be employed to aid selection of the 
most genotypically and antigenically diverse clones. Field trials would be required to test the 
efficacy of such a vaccine. The use of cloned parasites would eliminate the concerns 
associated with the loss of minor genotypic components from uncloned parasite populations 
  
 
and enable the parasite composition of the vaccine to be measured with greater precision, 
thereby improving the quality control of vaccine batches. 
However, until a more standardised vaccine is formulated, it remains essential to 
monitor the composition of different batches of the current vaccine, especially if the stocks 
used for vaccine production have been subjected to additional passages through cattle and 
ticks. The results of the current study provide useful reference data on which to establish 
molecular typing methods for monitoring the composition of the vaccine. 
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Figure legends 
 
Fig. 1. Illustration of the numbers and relative frequencies of micro- and mini-satellite alleles 
detected in the three components of the Muguga cocktail vaccine (Muguga, Serengeti and 
Kiambu 5). Alleles are denoted by different fill patterns, the black shaded allele representing 
the most abundant allele in the Muguga isolate.  
 
Fig. 2. Results of principal co-ordinate analysis of satellite typing data obtained for the 
individual components of the Muguga cocktail vaccine (Muguga, Serengeti and Kiambu 5) 
and the four batches of the Muguga cocktail vaccine (ILRI 0801-0804). 
 
Fig. 3. Illustration of the number and relative frequencies of micro- and mini-satellite alleles 
detected in four batches of the Muguga cocktail vaccine (ILRI 0801-ILRI 0804, labelled 1 - 
4). Alleles are denoted by different fill patterns, employing the same key used in Fig. 1. 
 
Fig. 4. Illustration of the numbers and relative frequencies of antigen gene alleles found 
using high throughput multi-locus sequencing of genes encoding CD8 antigens in the three 
components of the Muguga cocktail vaccine (Muguga, Serengeti and Kiambu 5) and the 
Marikebuni stock. Alleles are denoted by different fill patterns, the black shaded allele 
representing the most abundant allele in the Muguga isolate. The results for Tp2 (Tp2F) are 
based on forward sequence reads only. The National Center for Biotechnology Information 
(NCBI, USA) sequence read archive (SRA) accession number for these sequence data is 
SRP065583. 
 
  
 
Supplementary figure legend 
 
Supplementary Fig. S1. Amino acid sequences of Tp9 alleles obtained from five cloned 
Theileria parva populations (Muguga 3308, Uganda 3569, Boleni 3198, Marikebuni 3292 
and Mariakani 3178) and a variant allele (MC Kiambu 5) detected in the Kiambu component 
of the Muguga cocktail vaccine. The Muguga 3308 sequence, which is identical to the 
reference genome sequence, is shown as the reference sequence. Amino acid residues 
conserved in the other alleles are denoted by dots and deleted regions are denoted by 
dashes. 
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Table 1. Sequences of Theileria parva gene primers incorporated into fusion primers, primer 
concentrations and annealing temperatures used to generate PCR amplicons from antigen 
genes for high throughput sequencing.  
Gene Primer sequences (5′ – 3′) Concentration (pmol/reaction) 
Annealing 
temp. (°C) 
Amplicon 
sizea  
 
Tp1 for-CTGGTGTACAATTTGGTGGG 
rev-AACTTNMCTTCTTGCGAACC 
20 
20 55 428 
Tp2 
for-ATGAAATTGGCCGCCAGATTA 
for-GCCAGATTAATHAGYCTTTAC 
rev-AGATTTGTCACTAYCTGTWBYAGG 
rev-AGATTCGTCCTCAYCTGTWBYAGG 
10 
10 
25 
25 
49 492 
Tp3 for-AGCAGATTTCACTCAAGCTGC 
rev-TCCCCCAGAACATTAAACGG 
20 
20 54 407 
Tp4 for-GCAACACAATACTTTGCAGG 
rev-CCTCAAACACWCCACAAGTTCC 
10 
10 54 424 
Tp5 for-GTATGCTCGGTAATGGCAG 
rev-GATTTTGGTCGCTTCAGGC 
10 
10 55 347 
Tp6 for-CGTCCAATAATTTACGATGTGAG 
rev-GCTTAAGTGGGTTAAGGAGACA 
10 
10 55 326 
Tp7 for-TGAAGAAGGACGACTCGCAC 
rev-TCCTCGTCAGTGACGTCGG 
20 
20 58 292 
Tp8 for-ATCCACAACCAAGTGCCCAG 
rev-TGCTATTGCGAGTCAACAG 
10 
10 54 305 
Tp10 for-GGTCGTCTGACAATAACC 
rev-CTAMCATGTAAATCCAGC 
10 
20 49 314 
a
 The expected amplicon sizes (excluding the adaptor and Multiplex Identifier (MID) sequence of the 
fusion primer), based on the Muguga reference genome sequence. 
  
  
 
Table 2. Summary of numbers and alleles and their lengths (bp) detected in the Muguga 
cocktail Theileria parva vaccine by typing with 15 mini- and microsatellite markers 
Allele sizes (bp) detected for each satellite marker 
 
Chromosome 1 
  
Chromosome 2  Chromosome 3 
  
Chromosome 4 
ms2 MS3 MS7 MS8  ms7 MS14 MS15 MS19  MS21 MS25 MS27 MS30  MS33 MS39 MS40 
359a 258 309 311  170 340 204 295  325 324 209 213  214 263 188 
113 307 289 331  145 
 
116 304  245 309 149 189  
 
214  
  
372 263  
  
321  
 
255 
  
 
 
  
   
321  
 
 
  
   
  
 
 
  
aThose listed in the first horizontal row  are the alleles represented by black fill in Figs. 1 and 3. The 
alleles in the reference genome are indicated by grey shading. 
 
  
  
 
Table 3.  Numbers of Theileria parva antigen gene sequence alleles and total number of 
polymorphic residues present in allelic variants detected in the components of the Muguga 
cocktail vaccine (Kiambu 5, Serengeti and Muguga).   
 
Gene Total number 
of sequence 
readsa 
Polymorphic 
nucleotides 
No. alleles 
(nucleotide 
level) 
Polymorphic 
amino acids 
No. alleles 
(amino acid 
level)  
Tp1 6,156 0/393 1 0/131 1 
Tp2 1,596 2/290 2 2/96 2 
Tp3b 7,196 16/366 3 7/110 3 
Tp4b 4,314 41/382 4 0/40 1 
Tp5b 16,214 4/308 2 0/62 1 
Tp6 4,263 10/291 3 0/96 1 
Tp7 13,356 7/253 2 1/84 2 
Tp8 11,364 0/262 1 0/87 1 
Tp10b 12,360 3/277 2 1/59 2 
aThe total of sequence reads for the Muguga cocktail is the sum of reads obtained for each of the 
individual stocks. b These genes contain introns, accounting for the discrepancies between nucleotide 
and amino acid lengths.  
  
 
Table 4.  Amino acid sequences of variant CD8 T cell epitopesa detected within the Muguga 
cocktail and the Marikebuli stock of Theileria parva.  
 
Origin of parasite 
material 
Tp1 antigen 
 
Tp2 antigen 
 
 Tp1214-224 
 
Tp227-37 Tp240-48 Tp249-59 
 
Muguga cocktail 
 
VGYPKVKEEML  SHEELKKLGML DGFDRDALF KSSHGMGKVGK 
SDEELNKLGML 
 
Marikebuni stock 
 
VGYPKVKEEML 
VGYPKVKEEII 
 SHEELKKLGML 
SDEELETLGML 
SEAELRKMGMI 
DGFDRDALF 
PNPDKEKLF 
GNFDRELLF 
KSSHGMGKVGK   
KSSHGMGKIGK 
LTSKAMMTVGK 
 
a Residues showing amino acid substitutions compared with the reference sequence are bold and 
highlighted in grey.  
 
 
  
  
 
Table 5.  Numbers of Theileria parva antigen gene sequence alleles and total number of 
polymorphic residues present in allelic variants detected in the Marikebuni stock.  
 
Gene Total number 
of sequence 
reads 
Polymorphic 
nucleotides 
No. alleles 
(nucleotide 
level) 
Polymorphic 
amino acids 
No. alleles 
(amino acid 
level) 
Tp1 290 4/393 2 2/131 2 
Tp2 1,484 107/290 3 53/96 3 
Tp3a 352 0/366 1 0/110 1 
Tp4a 530 0/382 1 0/40 1 
Tp5a 4,771 4/308 2 0/62 1 
Tp6 1,933 0/291 1 0/96 1 
Tp7 1,875 3/253 2 0/84 1 
Tp8 15,445 0/262 1 0/87 1 
Tp10a 12,267 3/277 4 1/59 2 
a These genes contain introns, accounting for the discrepancies between nucleotide and amino acid 
lengths. 
  
  
 
Table 6. Comparison of the number of alleles detected for the Tp1, Tp2 and Tp9 gene 
sequences in the Muguga cocktail vaccine stabilates and the Marikebuni stock, with the 
number of alleles detected previously in field isolates of Theileria parva. 
Source of 
parasite material 
Number of 
isolates 
Tp1 alleles  Tp2 alleles  Tp9 alleles 
  DNA Amino 
acid 
 DNA Amino 
acid 
 DNA Amino 
acid 
Vaccine stocks:          
Muguga cocktail 3 1 1  2 2  2 2 
Marikebuni 1 2 2  3 3  4 4 
Field isolatesa:          
Cattle 41 12 10  5 4  nt nt 
Buffalo 41 26 26  38 38  nt nt 
aNumbers of alleles detected by sequencing Tp1 and Tp2 genes in 82 field isolates of T. parva 
reported by Pelle et al. (2010).  
nt, not tested.  
 
  
  
 
 
Graphical abstract 
  
  
 
Highlights 
• Genotyping and gene sequencing reveal limited diversity in a live Theileria parva vaccine 
• Two of the vaccine components show a high level of similarity at all loci. 
• The vaccine contains very little of the diversity found in field T. parva. 
• The vaccine is suboptimal for generating immunity again diverse parasite strains.  
• The presence of minor genotypic components poses difficulties for quality control.  
 
